



## **Third Quarter and First Nine Months 2022 Financial Results and Business Update**

November 16, 2022

## CureVac Speakers



Franz-Werner Haas

Business Update

Chief Executive Officer

Ulrike Gnad-Vogt

Program Update

Interim Chief Development Officer

Ronald Plasterk


Program Update

SVP Science & Innovation

Pierre Kemula

Financial Update

Chief Financial Officer



## Forward-Looking Statements



The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov).

## Selected Key Developments



### Prophylactic Vaccines: Executing on infectious disease program

In collaboration with GSK

- **Four Phase 1 clinical trials** currently ongoing with unmodified and modified mRNA constructs in **COVID-19** and **flu**
- **All trials on track** to deliver data in **early Q1 2023** to identify best performing candidate per indication for later-stage development



### Oncology: Building a cancer vaccines portfolio

- Advancing our **antigen discovery technologies** from **recent acquisition** of Frame Cancer Therapeutics
- Driving oncology strategy based on progress with our **second-generation mRNA backbone**
- Preparing for **two clinical proof of principle studies** to **validate** and **optimize** second-generation backbone approach

### Oncology Enablers: Manufacturing and delivery Technologies

- **The RNA Printer®** on track to support rapid **clinical screening** of new antigens; application for manufacturing licenses **submitted**
- Proprietary **LNP development** – new LNP composition provides highly **localized, stable** and **PEG-free** mRNA delivery

### CV8102: Non-coding RNA immuno-modulator

- Data confirm CV8102's safety and ability to strongly **mobilize the immune system** against tumors
- Phase 1 immune profiling data in **heavily pretreated** expansion cohort shows **broad systemic immune activation**




### Financial Update


- Cash position of **€540.9 million** as of September 30, 2022

# CureVac Pipeline: A Diversified Portfolio



AREA	PROGRAM	CANDIDATE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
PROPHYLACTIC VACCINES	1 <sup>st</sup> -Generation	COVID-19	CVnCoV <sup>1)</sup>	(unmodified mRNA)		
	2 <sup>nd</sup> -Generation	COVID-19		<b>CV2CoV</b>	(unmodified mRNA)	
				<b>CV0501</b>	(modified mRNA)	
	2 <sup>nd</sup> -Generation	Influenza		<b>CVSQIV</b>	(unmodified mRNA)	
	Infectious Diseases	Other		<b>FLU SV mRNA</b>	(modified mRNA)	
				Four undisclosed targets		
	1 <sup>st</sup> -Generation	Rabies	CV7202			
ONCOLOGY	Diverse Projects		Rota, malaria, universal influenza			
	Solid tumors <sup>2)</sup>		CV8102			
	Neoantigens		<b>Antigen discovery engine</b> based on new technologies acquired with Frame Cancer Therapeutics			
	Tumor Associated Antigens					
MOLECULAR THERAPY	Cas9 gene-editing		CRISPR Therapeutics collaboration			
	Liver Diseases		REBIRTH-Research Center collaboration			
	Ocular Diseases		Shepens Eye Research Institute collaboration			
	Therapeutic Antibodies		Genmab collaboration			



 Data expected in early Q1 2023 will inform **later-stage clinical trial development** of selected candidates

## Strategic Pillars to Increase Momentum in the Oncology Area



### INDUCTION OF T CELL RESPONSES

#### APPLY CURRENT mRNA TECHNOLOGY ADVANTAGES

- Taking advantage of our **technology advances**
- Validating current **T cell induction** mechanisms
- Optimizing current **technology approaches**

#### BUILD PIPELINE OF CANCER VACCINE CANDIDATES


- Accessing **novel classes** of antigens
- Exploiting **synergies** with other cancer treatments
- Leveraging agility of **The RNA Printer®**

#### ADD HIGHLY COMPLEMENTARY PLATFORMS

- Extended **antigen discovery** strategies
- New technologies for **immuno-modulation**
- Approaches for vaccine **design optimization**


### Focus on Cancer Vaccines


# Complementing Core Competencies in Oncology With Innovative Platforms







# Leveraging Data on the Full Inventory of Genomic Changes




 Whole Genome Sequencing of the tumor

 Short- and long-read RNA sequencing

+

 Prediction of expressed **frame** sequences


  
Potentially immunogenic **frame** neo-antigens

**Conventional** antigen discovery is restricted to mutations in the **tumor exome**

CureVac leverages the **full tumor genome** and tumor-specific **expression analysis**

**Powerful bioinformatics** use the full genetic inventory to identify potentially immunogenic neo-antigens as novel **cancer vaccine candidates**

# Mapping the Totality of Genomic Changes for Targeted Cancer Vaccination



## Framome\*

Foreign proteins as potential **vaccine targets**




\*Lung cancer patient sample

**Exome sequencing** offers only **limited insights** into genetic changes of the tumor


**Whole genome sequencing** provides **full inventory** of structural variations and other tumor antigens (such as TAAs, retroviral HERVs etc.)

# Identifying Shared Neo-Antigens Across Cancer Patients and Cancer Types

## Framome of tumor patient 1




## Framome of tumor patient 2



Shared **frame** neo-antigen  
expressed in subset of cancer patients

# Oncology Roadmap Leverages Full Spectrum of Technologies



# Optimizing Treatment with Off-the-Shelf and Personalized Vaccine Candidates



**Off-the-shelf**  
shared neoantigen  
& TAA candidates

- Seizes data on **frequently shared antigens** across patients and cancer types
- Aims for **highest antigen coverage** among patients to provide broadly applicable treatment options

**Personalized**  
cancer vaccine  
candidates



- Applies **deep analyses** to obtain detailed **personalized antigens** on a patient's tumor
- Aims to **precisely tailor** a **personalized** cancer vaccine to the patient's **individual antigens**


# CV8102: Data Demonstrates Preliminary Efficacy in Combination Cohort

Phase 1 Expansion Study in PD-1 Refractory Melanoma



## Phase 1 expansion study

Combination cohort: CV8102 + anti-PD-1 antibodies



- **30 patients treated** in the combination cohort
- **40% pretreated** with anti-CTLA-4 antibodies
- **Partial response** in five patients (17%)
- Responses **durable** for up to **one year**


# CV8102: Activation of Broad Immune Responses In Blood and Tumor

Phase 1 Expansion Study in PD-1 Refractory Melanoma




## Patient Biopsy Example: Tumor Microenvironment

Partial responder in combination cohort




● SOX10<sup>+</sup>    ● CD8<sup>+</sup>  
● CD3<sup>+</sup>    ● CD3<sup>+</sup>CD4<sup>+</sup>  
● CD4<sup>+</sup>    ● CD3<sup>+</sup>CD8<sup>+</sup>




## Full Combination Cohort: Gene Enrichment Analysis

Gene sets enriched in day 1 vs. day 2 samples




## Biodistribution

Localization of antigen expression in mice\*




## Systemic interferon alpha / cellular activity

Induction of interferon alpha / interferon gamma in mice\*



## Humoral activity

Induction of neutralizing antibody titers against rabies in mice\*







## New LNP Composition Exhibiting Good Stability in Dried State at 25°C



### mRNA integrity HPLC-based assay



### LNP integrity Encapsulation efficiency\*




# Envisioning a Future Oncology Workflow Enabled by The RNA Printer®



## External workflow

## Internal CureVac workflow



## Cash and Condensed Consolidated P&L Data



	December 31, 2021	September 30, 2020
(in € millions)		
<b>Cash and Cash Equivalents</b>	<b>811.5</b>	<b>540.9</b>

	Three months ended September 30,		Nine month ended September 30,	
(in € millions)	2021	2022	2021	2022
Revenue	29.3	11.2	61.8	55.7
Cost of Sales, Operating Expenses & Other Operating Income	-172.4	-63.6	-468.5	-183.6
<b>Operating Result</b>	<b>-143.1</b>	<b>-52.4</b>	<b>-406.7</b>	<b>-127.9</b>
Financial Result	-0.4	4.7	-1.2	7.5
<b>Pre-Tax Loss</b>	<b>-143.5</b>	<b>-47.7</b>	<b>-407.9</b>	<b>-120.4</b>

## Summary and Highlights



Strong expansion of **operational bandwidth** and further extension of applications for CureVac's mRNA technology and expertise



Progress across three core competencies of **technology platform, development pipeline** and **manufacturing** is propelling forward corporate development



**Four clinical trials** in infectious diseases on track to provide **meaningful data** to **assess candidates** for a later-stage development in COVID-19 and flu



Firing up **antigen discovery engine** Frame Cancer Therapeutics to develop novel cancer vaccine candidates enabled by broad **technology expansion**



**Strong cash position** of €540.9 million for executing on programs and priorities for the **rest of 2022** and **2023**





**Thank you for your  
attention**

CureVac  
[www.curevac.com](http://www.curevac.com)